Nirmatrelvir/Ritonavir Pfizer Dosing Information | Rwanda

Nirmatrelvir/Ritonavir Pfizer

Home

About

Efficacy

Trial Design

Safety

Important Safety Information

Safety & Tolerability

Dosing

Dosing Information

Dose Adjustments

Drug Interactions

Medical Information

Visit the Pfizer Medical Information Africa Website for Healthcare Professionals

Submit a medical question to Pfizer

To report an adverse event, please contact [email protected]

Nirmatrelvir/Ritonavir Pfizer is taken orally, twice daily for 5 days¹

Treatment should begin as soon as possible following a positive test and ≤5 days of symptom onset.

Nirmatrelvir/Ritonavir Pfizer recommended dosage for 5 consecutive days¹

Morning Dose

Two pink 150-mg tablets of nirmatrelvir
One white 100-mg tablet of ritonavir

Patients should take all 3 tablets together.

Evening Dose

Two pink 150-mg tablets of nirmatrelvir
One white 100-mg tablet of ritonavir

Patients should take all 3 tablets together.

Nirmatrelvir/Ritonavir Pfizer dosing instructions¹

Nirmatrelvir/Ritonavir Pfizer can be taken with or without food
The tablets should be swallowed whole and not chewed, broken, or crushed
If a dose of Nirmatrelvir/Ritonavir Pfizer is missed within 8 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 8 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose
If a patient requires hospitalization due to severe or critical COVID-19 after starting treatment with Nirmatrelvir/Ritonavir Pfizer, the patient should complete the full 5-day treatment course at the discretion of his/her healthcare provider.

EXPLORE MORE

Efficacy & trial design

Discover the efficacy data and trial design of EPIC-HR.

Efficacy

Trial design

Reference: 1. Nirmatrelvir/ ritonavir Pfizer Summary of Product Characteristics.

Dosing

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

To report an adverse event, please contact [email protected]
Click here to Submit a Medical Question.
Terms of Use
Cookies & Privacy Policy
Contact: KENYA OFFICE: Pfizer Laboratories (Pty) Ltd Vienna Court, First Floor West Wing, State House Crescent, State House Road, Nairobi Kenya, PO Box 18244-00500.
Tel: +254(0)5134110.
Pfizer.com

This site is intended only for Rwanda health care professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

Disclaimer: The product is not yet licensed by the Board of Health of Rwanda (Rwanda FDA). The product has however obtained prior Board of Health approval for supply to Accord program channels in Rwanda.

You are now leaving Accord Portal to access Pfizer Medical Information Portal

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.